Investigators have used base editing to create a treatment for multisystemic smooth muscle dysfunction syndrome, which has ...

The firm's commercialization push is fueled by $35.6 million from a recent Series C financing and a $15.5 million ...

Phase II/III data showed that advanced gastric cancer patients on anbenitamab and chemotherapy fared better than those on standard therapy.

Autonomous AI tools have great potential in supporting precision medicine, but developers are still figuring out how to deploy them in patient care.

Some feel the guidance may encourage consistent follow-up of overall survival after accelerated approvals, but others remain focused on speeding new drugs to patients.

The company announced results from a Phase Ib trial of the drug as a first-line monotherapy for EGFR PACC-mutated NSCLC.

Cambridge, Massachusetts-based Amylyx announced pricing of an underwritten public offering of 17,500,000 shares of its common stock at a public offering price of $10 per share. The firm has also ...

Sheba will extend the use of Imagene's cross-modality intelligence engine and suite of tools, initially deployed in lung cancer, across cancer indications.

The firm said it will enroll more ovarian cancer patients in its ongoing Phase II trial to gather data for a regulatory submission for rezatapopt to the FDA.

The company will use the funds to advance a CAR T-cell therapy it is developing for treating AL amyloidosis, a bone marrow disease.

The firm implemented the change after an IRB reviewed initial pharmacokinetic data from the first two patients treated in the trial.

The AI-enabled assay is being developed as a potential companion diagnostic for AstraZeneca and Daiichi Sankyo's ADC Datroway.